Bipolar I Disorder

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

How should clinicians approach treatment when their patient disagrees with the diagnosis?

The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

New approval for schizophrenia and bipolar I disorder.

“The sooner you can recognize and diagnose bipolar, the sooner you can institute effective evidence-based treatments.”

The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.

How did patients with BDI and obesity fare in new research looking at quality of life issues?

Vladimir Maletic, MD, MS, and Andrew Cutler, MD, comment on the value of studying genetics and family history for diagnosing and treating bipolar 1 disorder.

Drs Vladimir Maletic and Andrew Cutler provide an overview of symptom differences between bipolar 1 disorder (B1D) and bipolar 2 disorder (B2D).

The FDA has accepted the NDA for aripiprazole 2-month, ready-to-use, long-acting injectable.

Gus Alva, MD, DFAPA, discusses key takeaways for the management of bipolar disorder.

Dr. Gus Alva shares his initial impressions on this case and treatment approaches to bipolar 1 disorder.

Gus Alva, MD, DFAPA, presents the case of a 23-year-old female diagnosed with bipolar 1 disorder.

Up to 20% of patients with bipolar disorder have 4 or more medications, so it is important to be aware of these common drug-drug interactions.

Dr Moukaddam discusses key takeaways for the management of bipolar disorder.

Nidal Moukaddam, MD, PhD, provides insight on the evolving treatment landscape for bipolar disorder and optimizing therapies for disease management.

Dr Moukaddam shares factors to consider when approaching the treatment of bipolar disorder.

Nidal Moukaddam, MD, PhD, presents the case of a 30-year-old male diagnosed with bipolar 1 disorder and shares her initial impressions on diagnosis.

Here are a few reminders to help avoid both toxicity and loss of effectiveness.

ECT played an important role in this patient's journey to recovery.

Today is World Bipolar Day! Celebrate with the freshest clinical pearls on bipolar disorder that Psychiatric Times has to offer.